MI-EATON
18.5.2023 12:31:30 CEST | Business Wire | Press release
Intelligent power management company Eaton today announced its eMobility business is now offering specialized high-power lock box (HPLB) power connectors for use in current and future electrified and internal combustion vehicle solutions. The HPLB connectors, a component of eMobility’s Power Connections portfolio, offer a space-saving profile, superior performance, cost savings and reduced manufacturing complexity. The HPLB connectors were designed and developed by Royal Power Solutions, a leading manufacturer of high-precision electrical connectivity components that Eaton acquired in 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230518005136/en/
Eaton’s specialized high-power lock box (HPLB) terminal system forms a connection in a unique way that provides improved contact force throughout the component’s service life. (Photo: Business Wire)
HPLB connectors provide protection against the elements, corrosion
“Eaton recommends use of sealed connection systems to meet reliability and durability requirements,” said Chris Mancuso, general manager, Power Connections, Eaton. “Additionally, we’ve designed our HPLB terminal system for high-current and high-temperature applications, up to 500 amps and 125 degrees Celsius, respectively.”
Traditionally, eyelet terminals within vehicle electrical components are not sealed, potentially exposing them to road spray and salt, which accelerates terminal galvanic corrosion. Corrosion can mitigate the power flow, leading to system failure.
The fully sealed connectors are also resistant to severe vibration and deliver a component service life that meets USCAR Safety Performance Requirements.
Innovative terminal contact methodology
Eaton’s HPLB terminal system forms a connection in a unique way that provides improved contact force throughout the component’s service life. Unlike traditional box and blade terminals, the connectors use Power Connections’ Connector Positive locks, which utilize an “inside-out” contact system with internal spring pressure and multiple contact points. The unique configuration provides a stronger connection than that of conventional box-and-blade connectors where the female terminal spring squeezes the male blade, which loosen when exposed to heat and vibration, resulting in a loss of power flow continuity and the possibility of corrosion.
“Power connectors, while a small component, are a critical design element to meet product performance and durability requirements,” Mancuso said. “Commercial fleet operators not only expect but require that all vehicle systems have a service life of at least 10 years.”
The unique connection also reduces heat radiating from the connection points by an average of six degrees Fahrenheit per contact. Many modern vehicles have up to 120 such contact points, so leveraging HPLB connectors leads to dramatic temperature mitigation and improved vehicle performance.
Reduces manufacturing complexity, potential for harmful production errors
Traditionally, eyelet terminals are manually connected by a production line worker wearing two sets of gloves for protection against high voltage and an air gun to tighten small nuts. If the connection is not precise every time it can result in a disruption in power flow. If the operator accidentally drops a nut into the component’s inner workings, it can short circuit the entire unit.
The HPLB connectors can be installed by a “pick-and-place” robot, allowing for precise and safe connections every time. Additionally, the HPLB sits flush, unlike traditional connector terminals, reducing space requirements within the vehicle.
“Our HPLB terminal connectors not only lower temperature, but provide extra current carrying capacity,” Mancuso said. “So, they are half the size and carry twice the current, and in some applications up to three times the current.”
Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power — today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.
Founded in 1911, Eaton is marking its 100th anniversary of being listed on the New York Stock Exchange. We reported revenues of $20.8 billion in 2022 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005136/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
